Abogen Biosciences Showcases mRNA Innovation at the 1st Annual Meeting of the International Society of Nucleic Acid Immunity

2024Year10Month14Date16Day,The First Annual Meeting of the International Society for Nucleic Acid Immunology (1st Annual Meeting of the International Society of Nucleic Acid Immunity`) was successfully held at the International Conference Center of the Papal Palace in Avignon, France.`. This international academic conference in the field of nucleic acid immunology aims to bring together scientists, researchers, and industry representatives from around the world to engage in in-depth discussions on the latest advancements in nucleic acid immunology, jointly promoting scientific development and technological innovation in this field. For more details about the conference, please see:https://www.nai-society.com/。

The venue for this conference is the historic Palais des Papes.Not only a hub of art and culture, but also a sacred place for the collision and integration of modern scientific thought. During the conference, experts and scholars from top research institutions conducted in-depth discussions on cutting-edge topics such as fundamental mechanism research and disease applications in the field of nucleic acid immunity.Highlights of this meeting includecGAS-STING DNARecent advances in sensory pathways, the combination of nucleic acid sensors with cancer immunotherapy, etc. Additionally, nucleic acid immunity in autoimmune diseases and emerging viruses.Immune Controlin areas such as these, also demonstrated the broad prospects of nucleic acid technology in the future biopharmaceutical market.。

This conference not onlyNucleic Acid Immunology FieldAcademiaProvided a platform for the exchange of ideas, and also forIndustryProvided a stage to showcase its own technical advantages.Abogen showcased at the conferenceThe company's foresight and technical strength in the field of nucleic acid drug research and development have attractedThe attention of many attendeesDr. Peng Gao, Vice President of Abogen BiosciencesmRNADr. Wenjie Zuo, Senior Researcher of Innovation (Nucleic Acid Science Department), represented the company at the conference and actively communicated with participants.。

Dr. Peng Gao (left), Vice President of Abogen BiosciencesmRNADr. Wenjie Zuo (Nucleic Acid Science Department, right), Senior Researcher of Innovation, at the conference site

As a leader in the innovative research and development of nucleic acid drugs, Abogen Biosciences is always committed to promoting the development and application of nucleic acid technology through close cooperation worldwide.Promote MoremRNAInnovative DrugsDevelopment。Based in China, serving the globe,Abogen asmRNAA leading enterprise with international competitiveness in the field will continue to contribute to the innovative development of the biopharmaceutical industry.

About Us

Abogen Biosciences (referred to as "Abogen") is an innovative biopharmaceutical company focusing on the research and development of messenger ribonucleic acid (mRNA) drugs. The company owns industry-leading, proprietary intellectual property rights in mRNA and nanodelivery technology platforms. It is one of the few mRNA drug research and development enterprises in China with complete value chain capabilities, covering all aspects from mRNA design, formulation development to large-scale production. The company has established a rich product pipeline, spanning multiple fields including infectious disease prevention and treatment, tumor immunology, protein replacement therapy, and mRNA-based COVID-19 vaccines.